-  ELIGIBILITY CRITERIA:

        Common Eligibility for Parts I and II

          -  Adults greater than or equal to 18 with malignant soft tissue and bone tumors and
             recurrent or progressive,metastatic solid tumors who have progressed on standard
             therapies except in adjuvant for high risk bladder cancer in Part I.

          -  Recurrent or progressive disease on prior standard therapies with known clinical
             benefit with the exception of adjuvant bladder cancer population.

          -  Performance Status: ECOG 0-1.

          -  Baseline LVEF by 2D Echocardiogram greater than or equal to 53%.

          -  Greater than or equal to 1 week since standard or investigational treatment for
             metastatic disease.

          -  Stable, concurrent use of hormone therapy for hormone receptor positive breast cancer
             is permitted.

          -  Hematologic parameters: ANC greater than or equal to 1000 cells/mm3, ALC greater than
             or equal to 300 cells/mm3, Hemoglobin greater than or equal to 9.0 gm/dL, WBC greater
             than or equal to 2,500 cells/mm3, platelet count greater than or equal to 75,000/mm3,
             PT/PTT less than or equal to 1.5X the upper limits of normal.

          -  Chemistry parameters: Creatinine less than or equal to 1.5 mg/dL, SGOT and SGPT less
             than or equal to 3X the upper limits of normal and total bilirubin less than or equal
             to 1.5 mg/dl, Alk PO4 less than or equal to 3X the upper limits of normal (except for
             patients with documented metastatic disease to bone and/or liver).

          -  Negative serum beta HCG if female and of childbearing potential.

          -  Negative HIV 1/2 serology and sample drawn for HTLV. Patients with HIV are excluded
             from participating on this clinical trial because their immunodeficiency would
             confound the evaluation of adverse events which would hinder meeting the primary
             objective.

          -  Negative serology for hepatitis B and C unless the result is consistent with prior
             vaccination or prior infection with full recovery.

          -  Willingness of female and male subjects to use effective contraception e.g. oral
             contraceptives, barrier device, intrauterine device, or condoms, during the study and
             for three months following the last dose of study vaccine. We suggest that subjects do
             not become pregnant or father a child during the study, and for 3 months following
             receipt of the investigational AdHER2 DC vaccine.

          -  Able to understand and provide Informed Consent.

          -  Patients with 1+ to 3+ HER2/neu expression by IHC or an equivocal or positive FISH
             result by 2013 ASCO/CAP guideline.

          -  Patients must have measurable disease, per RECIST 1.1.

        Part I Eligibility

          -  Naive to trastuzumab (Herceptin), pertuzumab (Perjeta) and lapatinib
             (Tykerb),ado-trastuzumab emtansine (Kadcyla) or other HER2-directed therapies.

          -  Malignancy as follows:

          -  Malignant soft tissue and bone tumors and recurrent or progressive, metastatic solid
             tumors who have progressed on standard therapies; or,

          -  Bladder cancer in the adjuvant setting (adjuvant bladder cancer patients):

               -  Tumor stage T3a, T3b, T4a, T4b and any node positive disease regardless of tumor
                  stage.

               -  Status-post primary cystectomy with curative intent.

               -  May or may not have received neoadjuvant cisplatin-based combination chemotherapy
                  per NCCN guidelines.

               -  May or may not have received adjuvant radiotherapy or chemotherapy based on
                  pathologic risk per NCCN guidelines.

               -  Greater than or equal to 6 weeks s/p primary surgery with curative intent.

          -  NOTE: Patients with breast, ovarian, cervical, colon, gastric/gastroesophageal
             junction, non-small cell lung, renal cell, bladder, malignant soft tissue and bone
             tumor, prostate cancer or other solid tumors.

        Part II Eligibility

          -  Malignant soft tissue and bone tumors and recurrent or progressive, metastatic solid
             tumors who have progressed on standard therapies.

          -  Recurrent or progressive metastatic disease after standard of care HER2-targeted
             therapies; i.e. trastuzumab (Herceptin), pertuzumab (Perjeta), lapatinib (Tykerb),

        ado-trastuzumab emtansine (TDM1) (Kadcyla) or other HER2-directed therapies.

        -Stable, concurrent use of tamoxifen or aromatase inhibitors for hormone receptor positive
        breast cancer is permitted.

        EXCLUSION CRITERIA:

          -  Pregnant women are excluded from this study because AdHER DC vaccine may have the
             potential for teratogenic or abortifacient effects. Because there is an unknown but
             potential risk for adverse events in nursing infants secondary to treatment of the
             mother with AdHER DC vaccine, breastfeeding should be discontinued if the mother is
             treated with AdHER DC vaccine.

          -  Patients with active CNS metastases or leptomeningeal involvement by tumor (patients
             with a history of brain metastases who have successfully treated for brain metastasis
             by surgery or radiation and who have not had any evidence of the new or progressive
             CNS disease for more than 12 months are eligible).

          -  Patients with rapidly progressing disease in the opinion of the Principal
             Investigator.

          -  Patients with inadequate bilateral peripheral venous or central venous catheter access
             for the required apheresis to allow generation of the autologous AdHER2 DC vaccine
             product.

          -  Clinically significant cardiac dysfunction defined as a history of > NYHA Class II
             symptoms, angina, congestive heart failure, myocardial infarction, arrhythmias or
             cardiac dysfunction requiring treatment or discontinuation of chemotherapy.

          -  History of changes in baseline LVEF that occurred during prior treatment with
             anti-HER2 treatment.

          -  Cumulative doxorubicin dose > 400mg/m2 (>450 mg/m2 for malignant soft tissue and bone
             tumor patients) or cumulative epirubicin dose > 800mg/m2.

          -  Use of any standard chemotherapy or other investigational agent(s) within 1 week of
             study enrollment.

          -  Use of systemic corticosteroid therapy within 2 weeks of study enrollment, including
             patients receiving replacement corticosteroid therapy. Note: only topical, inhaled and
             intranasal steroid therapy is permitted.

          -  Active systemic viral, bacterial or fungal infection requiring treatment.

          -  A medical history which the treating physician believes causes the patient to be
             excluded. This includes a remote history of cancer. Please note: squamous cell
             carcinoma, basal cell carcinoma and remote history of cancer with no evidence of
             recurrence for the past 5 years are eligible.